[go: up one dir, main page]

AR010369A1 - Antagonista de receptor vitronectina, su preparacion asi como su empleo. - Google Patents

Antagonista de receptor vitronectina, su preparacion asi como su empleo.

Info

Publication number
AR010369A1
AR010369A1 ARP970105994A ARP970105994A AR010369A1 AR 010369 A1 AR010369 A1 AR 010369A1 AR P970105994 A ARP970105994 A AR P970105994A AR P970105994 A ARP970105994 A AR P970105994A AR 010369 A1 AR010369 A1 AR 010369A1
Authority
AR
Argentina
Prior art keywords
preparation
well
job
receptor antagonist
vitronectin receptor
Prior art date
Application number
ARP970105994A
Other languages
English (en)
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of AR010369A1 publication Critical patent/AR010369A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antagonistas de receptor vitronectina, su preparacion así como su empleo. Son compuestos de la formula I, en donde A, B, D, E, F y G tienen lossignificados dados en las reivindicaciones, su preparacion y su empleo como medicamento. Loscompues tos son empleados como antagonistas de recetores devitronectina y como inhibidores de la resorcion osea.
ARP970105994A 1996-12-20 1997-12-18 Antagonista de receptor vitronectina, su preparacion asi como su empleo. AR010369A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653645A DE19653645A1 (de) 1996-12-20 1996-12-20 Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung

Publications (1)

Publication Number Publication Date
AR010369A1 true AR010369A1 (es) 2000-06-07

Family

ID=7815760

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105994A AR010369A1 (es) 1996-12-20 1997-12-18 Antagonista de receptor vitronectina, su preparacion asi como su empleo.

Country Status (19)

Country Link
US (1) US5990145A (es)
EP (1) EP0854145A3 (es)
JP (1) JPH10182617A (es)
KR (1) KR19980064419A (es)
CN (1) CN1200373A (es)
AR (1) AR010369A1 (es)
AU (1) AU729760B2 (es)
BR (1) BR9706386A (es)
CA (1) CA2225267A1 (es)
CZ (1) CZ411297A3 (es)
DE (1) DE19653645A1 (es)
HU (1) HUP9702509A3 (es)
ID (1) ID19245A (es)
IL (1) IL122643A0 (es)
NO (1) NO975975L (es)
NZ (1) NZ329429A (es)
PL (1) PL323968A1 (es)
TR (1) TR199701645A3 (es)
ZA (1) ZA9711315B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL350291A1 (en) 1998-12-23 2002-12-02 Searle & Co Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6545032B1 (en) 1999-09-17 2003-04-08 Torrey Pines Institute For Molecular Studies Synthesis of [3,5,7]-H-imidazo[1,5-a] imidazol-2(3H)-one compounds
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
US7176199B2 (en) * 2001-03-19 2007-02-13 Dainippon Pharmaceutical Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
IL161692A0 (en) 2001-11-13 2004-09-27 Dimensional Pharm Inc 14-benzodiazepine derivatives and pharmaceutical compositions containing the same
US7205315B2 (en) * 2003-09-27 2007-04-17 Sanofi-Aventis Deutschland Gmbh Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
CA2630415A1 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EA201200560A1 (ru) 2006-01-18 2012-09-28 Мерк Патент Гмбх Специфическая терапия, использующая интегриновые лиганды для лечения рака
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
ES2576643T3 (es) 2007-03-09 2016-07-08 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497164B2 (ja) * 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
US5204350A (en) * 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) * 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5648368A (en) * 1992-12-01 1997-07-15 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
DE69528829T2 (de) * 1994-05-27 2003-08-07 Merck & Co., Inc. Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
CZ203898A3 (cs) * 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
TR199801253T2 (xx) * 1995-12-29 1998-12-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
BR9612378A (pt) * 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
EP0796855B1 (de) * 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten

Also Published As

Publication number Publication date
BR9706386A (pt) 2003-04-22
CN1200373A (zh) 1998-12-02
AU729760B2 (en) 2001-02-08
KR19980064419A (ko) 1998-10-07
HUP9702509A3 (en) 2001-04-28
JPH10182617A (ja) 1998-07-07
PL323968A1 (en) 1998-06-22
TR199701645A2 (xx) 1998-07-21
CA2225267A1 (en) 1998-06-20
CZ411297A3 (cs) 1998-07-15
ZA9711315B (en) 1998-06-22
ID19245A (id) 1998-06-28
NO975975L (no) 1998-06-22
EP0854145A3 (de) 2000-03-22
EP0854145A2 (de) 1998-07-22
NZ329429A (en) 1999-05-28
NO975975D0 (no) 1997-12-19
IL122643A0 (en) 1998-08-16
AU4846497A (en) 1998-06-25
TR199701645A3 (tr) 1998-07-21
DE19653645A1 (de) 1998-06-25
US5990145A (en) 1999-11-23
MX9710389A (es) 1998-08-30
HUP9702509A2 (hu) 1999-06-28
HU9702509D0 (en) 1998-03-02

Similar Documents

Publication Publication Date Title
AR010369A1 (es) Antagonista de receptor vitronectina, su preparacion asi como su empleo.
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
AR007961A1 (es) Derivados de cicloalquilo como inhibidores de la resorcion osea y antagonistas de receptores de vitronectina, procedimiento para su preparacion y preparado farmaceutico.
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
EE200000778A (et) 4-bensüülpiperidiinalküülsulfoksiidi heterotsüklid ja nende kasutamine NMDA retseptori alaliikide suhtes selektiivsete antagonistidena
PT1379522E (pt) Derivados de di-hidro-benzo[b] [1,4] diazepina-2-ona como antagonistas i do r2glum
ATE507210T1 (de) Chinazolinon modulatoren von nukleinrezeptoren
DK1288205T3 (da) Nye phenylalanin-derivater
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
UY28519A1 (es) Derivados de quinazolina
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
BR9909486A (pt) Compostos calcilìticos
DE60112924D1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
EP1401431A4 (en) HUMAN GROWTH HORMONE ANTAGONISTS
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
DE60224723D1 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
MX9202616A (es) Nuevos hetariloxi-beta-carbolinos, su produccion y uso en agentes farmaceuticos.
MX9603045A (es) Antagonistas de los receptores endoteliales.
ATE400568T1 (de) Substituierte 4-(4-piperidin-yl-piperazin-1-yl)- azepan-derivate und ihre verwendung als tachykinin-antagonisten
UY26329A1 (es) Antagonistas de los receptores de vitronectina
DE69526738D1 (de) Endothelin-rezeptor-antagonisten

Legal Events

Date Code Title Description
FB Suspension of granting procedure